SKYE Earnings & Financial Statements
Skye Bioscience, Inc.
$1.60
-$0.09(-5.62%)
26
Overall
60
Value
10
Tech
10
Quality
Market Cap
$7.48M
Volume
26.54K
52W Range
$1.50 - $13.60
Target Price
$60.80
SKYE earnings and financial statements: Skye Bioscience, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
SKYE Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$58.16M | -$30.19M | -$34.74M | -$18.31M | -$7.85M |
| EBITDA | -$55.20M | -$24.91M | -$36.28M | -$18.69M | -$7.72M |
| Net income | -$55.92M | -$26.57M | -$37.64M | -$19.48M | -$8.52M |
| EPS (diluted) | $-1.41 | $-0.73 | $-5.37 | $-10.00 | $-5.00 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $28.31M | $72.76M | $11.94M | $9.11M | $9.86M |
| Total liabilities | $8.29M | $4.61M | $14.07M | $12.12M | $3.99M |
| Shareholders’ equity | $20.02M | $68.15M | -$2.13M | -$3.01M | $5.86M |
| Cash and equivalents | $5.88M | $68.42M | $1.26M | $1.24M | $8.98M |
| Long-term debt | $84.0K | $273.2K | $171.2K | - | $78.7K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$43.06M | -$25.24M | -$13.95M | -$12.74M | -$6.47M |
| Capital expenditure | -$6.3K | -$1.60M | -$12.6K | -$28.1K | -$90.9K |
| Free cash flow | -$43.07M | -$26.84M | -$13.96M | -$12.77M | -$6.57M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SKYE | $1.60 | -5.6% | 26.54K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |